PerkinElmer to Acquire Oxford Immunotec for ~$591M
Shots:
- PerkinElmer to acquire Oxford Immunotec for $22/ share with a premium of ~28.3% to the closing price/ share of $17.15 on Jan 5- 2021- making a total deal value $591M. The transaction is expected to be completed in H1’21
- The acquisition allows the PerkinElmer to strengthen its portfolio of advanced infectious disease testing solutions to include tuberculosis detection for better serving across the globe
- The deal will enable PerkinElmer to combine its channel expertise & workflow and testing capabilities with Oxford Immunotec’s proficiencies in T cell immunology with its test kits for latent tuberculosis
Ref: BusinessWire | Image: Oxford Immunotec
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com